Header Logo

Connection

MICHAEL BRAUN to Immunoconjugates

Back to Details
This is a "connection" page, showing publications MICHAEL BRAUN has written about Immunoconjugates.
MICHAEL BRAUN
Connection Strength
0.189
Immunoconjugates
  1. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol. 2023 08 01; 41(22):3796-3804.
    View in: PubMed
    Score: 0.189
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.